Relapse is still the major cause of failure of allogeneic stem cell transplantation in high-risk acute leukemia patients. Indeed, whoever the donor and whatever the transplantation strategy, post-transplant relapse rates are~30%, which is hardly satisfactory. The present phase 2 study analyzed the impact of adoptive immunotherapy with naturally occurring FoxP3+ T-regulatory cells (2 × 10 6 per kg) and conventional T lymphocytes (1 × 10 6 per kg) on prevention of GvHD and leukemia relapse in 43 high-risk adults undergoing full-haplotype mismatched transplantation without any post-transplant immunosuppression. Ninety-five percent of patients achieved full-donor type engraftment. Only 6/41 patients (15%) developed ⩾ grade II acute GvHD. Specific CD4 + and CD8 + for opportunistic pathogens emerged significantly earlier than after standard T-cell-depleted haplo-transplantation. The probability of disease-free survival was 0.56. At a median follow-up of 46 months (range 18-65 months), only 2/41 evaluable patients have relapsed. The cumulative incidence of relapse was significantly lower than in historical controls (0.05 vs 0.21; P = 0.03). These results demonstrate that the immunosuppressive potential of Tregs can be used to suppress GvHD without loss of the benefits of GvL activity. Humanized murine models provided insights into the mechanisms underlying separation of GvL from GvHD.
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Today, HLA-haploidentical hematopoietic stem cell transplantation (HSCT), whether T-cell replete or T-cell depleted, is a feasible option for patients with high-risk acute leukemia who do not have matched donors but is still associated with issues of transplantrelated mortality and post-transplant leukemia relapse. Conventional CD4+ and CD8+ T cells (Tcons) in the donor grafts have long been recognized as a double-edged sword. They facilitate engraftment, accelerate immune reconstitution, 1 and contribute to the elimination of residual disease, that is, the so-called GvL effect.
Studies in experimental models [2] [3] [4] and clinical observations 5, 6 established that the GvL effect depends on recognition of host histocompatibility Ags on leukemic cells, although hematopoieticand leukemia-specific responses may also occur. 7 As unselected T cells react against a multitude of host alloantigens and cause GvHD, GvL induction by conventional HSCT is rather a primitive form of leukemia immunotherapy. In T-cell replete HSCT, pharmacological immunosuppression for GvHD prophylaxis and treatment is non-specific and only partially successful. More importantly, it may compromise the T-cell-induced GvL effect and consequently post-transplant relapse is still the major cause of treatment failure in high-risk acute leukemia (AL) patients. Indeed, whoever the donor (matched sibiling, matched unrelated, unrelated cord blood and haplo-family member), and whatever the transplant strategy, relapse rates are~30%, which is hardly satisfactory. [8] [9] [10] [11] After T-cell-depleted haplo-transplant, the cumulative incidence of post-transplant relapse is similar in high-risk ALL patients and in those with AML who were not transplanted from natural killer (NK) alloreactive donors. Another major issue is slow post-transplant immune recovery owing to the few residual T lymphocytes in the graft and in vivo ATG-linked T-cell depletion. Thus, recipients remain susceptible to life-threatening opportunistic infections for several months after transplantation. [12] [13] [14] [15] [16] All the evidence points to the fact that a high number of donor T cells in the graft are needed to rebuild immunity and exert a GvL effect. As GvHD and GvL both derive from alloreactivity, the key challenge is to determine how alloreactive T cells can be manipulated to spare normal cells yet kill leukemic cells. Separating the GVL effect from GvHD and improving immune reconstitution are the two targets when designing haploidentical graft composition in today's world.
In the search for a viable strategy, attention is focused on a thymic-derived CD4+CD25+ FoxP3+ T-cell subpopulation, which has a physiological role in maintaining immunological selftolerance and immune homeostasis. 17, 18 The question was whether the immunosuppressive potential of donor FoxP3+ regulatory T cells (Tregs) could be used to separate GvHD from Tcon-induced GvL effect.
In several murine models of bone marrow transplantation across MHC class I and II barriers, lethal GvHD was suppressed when freshly isolated 19, 20 or ex vivo expanded polyclonal 21 or recipient-type 22 FoxP3+Tregs were co-infused with conventional T lymphocytes (Tcons). Treg in vivo dynamics showed that infusion of freshly isolated polyclonal Tregs was followed by activation, robust expansion of alloantigen-specific Tregs in lymph nodes and migration to GvHD target tissues (skin, gut, liver and lung). 20 During their effector phase Tregs markedly reduced early alloreactive T-cell proliferation in lymph nodes and perhaps in non-lymphoid tissues by means of several mechanisms, for example, via interaction with APCs in priming sites. 23, 24 At the same time, adoptive transfer of Tregs was associated with accelerated donor lymphoid expansion of a diverse TCR V beta repertoire and improved immune reconstitution, thus protecting mice from lethal CMV infection. 20 Good immune reconstitution 1 was also observed in a mismatched transplant mouse model of HSCT that was set up to exclude thymic output so as to replicate adult human immune reconstitution from only mature T cells in the graft. 25 Adoptive immunotherapy with Tregs and Tcons did not impair Tcon control of neoplastic cell line expansion, such as A20 leukemic cells of BALB/c origin, BCL1 lymphoma and P815 mastocytoma. 26, 27 Similarly, in humanized mouse models, human Treg-Tcon immunotherapy eradicated human primary myeloid leukemia and lymphoblastic leukemia cell lines without triggering GvHD. 28 These insights from animal models prompted us to evaluate the impact of Treg-Tcon adoptive immunotherapy in the clinical setting of HLA-haploidentical transplantation. We designed a haplo-transplantation protocol that focused on co-infusion of a high number of broad repertoire T cells and freshly isolated CD4+CD25+, FOXP3+ Tregs, without any post-transplant immunosuppression.
Obtaining a suitable number of Tregs under GMP conditions was the main obstacle. A fully automated immunomagnetic procedure (CliniMACS TM Instruments, Miltenyi Biotec, Bergisch Gladbach, Germany) selected naturally occurring CD4+CD25+ FoxP3+ Tregs by depleting the leukapheresis product of CD8 +/CD19+ cells and then positively immunoselecting CD25+ cells. The final fraction contained between 2 and 400 hundred million cells with about 80% FOXP3+. 29 Figure 1 illustrates protocol timing. In brief, the conditioning regimen included TBI (8 Gy in single fraction at fast dose rate with lung shielding on day -10), thiotepa (4 mg/kg per day on days -10 and − 9), fludarabine (40 mg/m 2 per day from days -10 to -6). The first 25 patients also received cyclophosphamide (35 mg/kg per day on days -7 and -6). To reduce extra-hematological toxicity, the other 18 were given alemtuzumab lot # 84039D 8 or thymoglobulin 3-7 mg/Kg 12 instead of cyclophosphamide. Anti-T antibodies were administered 21 days before transplant to prevent interference with Treg-Tcon adoptive immunotherapy. All patients received freshly isolated donor Tregs (mean 2.5 per kg ± 1) on day − 4, followed by Tcons (mean 1.1 per kg ± 0.6) and CD34+ cells (mean 9.7 × 10 6 per kg ± 3.1; mean contaminating T cells: 0.8 × 10
4 per kg ± 0.4) on day 0. The 4-day interval between Treg and Tcon infusions was in accordance with animal data indicating that early Treg administration provided greatest protection against GvHD. 30 No pharmacological post-transplant GvHD prophylaxis was given.
Starting in September 2008, 43 consecutive AL patients (median age 40 years; range 18-65) were treated, with the last patient being recruited in December 2012. 28 Thirty-three had AML (18 CR1 and 15 CR2), 10 had ALL (7 CR1; 3 in ⩾ CR2).
All patients who were transplanted in CR1 were at high risk of relapse because of adverse molecular, cytogenetic and clinical features. Outcomes were compared with 114 high-risk CR1, ⩾ CR2 AL patients (50 ALL; 64 AML; median age 37 years), from previous haploidentical HSCT trials. [12] [13] [14] All had received a similar TBI-based conditioning regimen and a graft, which included 10 × 10 6 per kg ± 2.1 CD34 + cells with 1 × 10 4 to 1 × 10 5 per kg body weight, contaminating T lymphocytes.
Median age, the proportion of AML vs ALL, and remission status were similar in the two cohorts. All patients in both cohorts who In 2, GvHD responded rapidly to a short course of immunosuppression, only one of these patients developed chronic GvHD. 28 Therefore, as previously reported, 29 Tregs controlled the alloreactivity of up to 1 × 10 6 per kg T lymphocytes, which is about 2log more than the threshold dose for GvHD. Brunstein et al 31 who supplemented GvHD prophylaxis in double-unit UCB transplantation with ex vivo expanded polyclonal Tregs, also reported a significantly reduced incidence of grade 2-4 GvHD.
Adoptive immunotherapy with Tregs did not compromise general immunity or blunt responses to infectious agents. There was a rapid, sustained increase in peripheral blood T-cell subpopulations. Specific CD4 + and CD8 + for opportunistic pathogens such as Aspergillus fumigatus, Candida albicans, CMV, ADV, HSV and VZV toxoplasma emerged significantly earlier than after standard haploidentical transplantation (at each time point P o0.0001). Prevention of CMV disease improved markedly, with no CMV-related deaths, which had been a major cause of mortality in the historical control group. 29 The cumulative incidence of nonrelapse mortality was 0.40, which fell to 0.21 in 18 patients who received anti-T antibodies in the conditioning. Better outcomes may have been linked to cyclophosphamide suspension as less extra-medullary toxicity was associated with the lack of severe veno-occlusive disease and multi-organ failure. Causes of nonrelapse death were as follows: veno-occlusive disease in three patients who were heavily pre-treated until a few days before transplantation, GvHD (3), adenoviral infection (2), bacterial sepsis (2), HHV6 infection (2), multi-organ failure (1) systemic toxoplasmosis (1). Lung (3) and central nervous system (1) aspergillosis in patients with invasive fungal disease before transplantation.
At a minimum follow-up of 18 months, 23/41 patients are alive and well with a DFS probability of 0.56 vs 0.39 in controls (P = 0.07), indicating a trend towards better survival under the Treg/Tcon protocol. To reduce the risk of post-transplant infectionrelated morbidity and mortality, it might be worth increasing the number of Tcons in the graft by means of CD3+CD45RO+ cells. 32 In the present series, infusion of Tcons under the Treg protective umbrella, in the absence of post-transplant pharmacological immunosuppression, guaranteed almost total control of AML and ALL relapse without being associated with GvHD. Impressively, the T-cell-dependent GvL effect was so powerful that it masked the anti-AML activity exerted by post-transplant generation of alloreactive donor-vs-recipient NK cell repertoires. 15, 16, 33 At a median follow-up of 46 months (range 18-65 months), only 2/41 evaluable patients have relapsed. 28 Both had NPM+Flt3+AML in molecular relapse at time of HSCT and had received transplants from non-NK alloreactive donors. The cumulative incidence of relapse was significantly lower than in historical controls (0.05 vs 0.21; P = 0.03). Multivariate analysis identified Treg-Tcon adoptive immunotherapy as the only predictive factor (relative risk 0.06; 95% CI, 0.02-0.35; P = 0.02). Figure 2 reports relapse rates in the Treg-Tcon treated patients and historical controls who underwent haplo-HSCT from NK alloreactive and non-NK alloreactive donors.
The mechanisms underlying Treg suppression of GvHD with no loss of GvL activity remain to be fully elucidated. We know that in animal models, Edinger et al observed that Tregs inhibited early expansion of alloreactive donor T cells and their capacity to induce GVHD. They did not, however, inhibit co-transplanted Tcon activation and cytotoxicity against leukemia and lymphoma cells in vitro and in vivo. 26 T cells harvested from the bone marrow of our humanized mice killed human leukemia cells and autologous PHA blasts in vitro, thus confirming their cytotoxic activity was preserved and indicating that alloantigen recognition underlay the GvL effect. 28 The GvL effect could also be related to Treg migratory properties, which are linked to homing molecule expression in diverse sites.
In the clinical transplant setting, few infused donor Tregs are likely to migrate to the bone marrow as they are almost 100% RO+ with very low CXCR4 expression. One might hypothesize that failure of donor Tregs to home to the bone marrow might have exposed leukemic stem cells to largely unopposed donor T-cell alloreactivity.
Whatever the mechanism(s), there was no need for posttransplant pharmacological prophylaxis against GvHD, which, as we know, could impair the GvL effect. Thus, without the risk of Tcon activity being inhibited, 1 × 10 6 per kg T-effector cells were sufficient to eradicate minimal residual disease. Consequently, the 30-35% incidence of relapse, which is generally reported by conventional T-cell replete HSCT in high-risk AL patients, was almost totally eliminated.
In conclusion, we are confident that the innovative use of Tregs and Tcons is a major advance on conventional HSCT, which, as leukemia immunotherapy, is associated with severe side effects and is only partially efficacious.
Years of research have taken us to new 'designed' grafts containing megadose hematopoietic progenitors to allow engraftment 13, 34, 35 in conjunction with appropriate number of Tcons and T Tregs, enabling prompt immune reconstitution and marked GVL reactivity without GVHD. The decades-long struggle to enhance the GvL effect of 'megadose' haplo-HSCT while suppressing GvHD may finally be coming to an end.
